In the 2023 International Panel’s diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), one of six core clinical demyelinating events (core events) is required: optic neuritis (ON), myelitis, acute disseminated encephalomyelitis (ADEM), cerebral monofocal or polyfocal defici...
Y. Matsumoto, Naoki Yamamoto, K. Kaneko et al.· Brain Communications· 0 citations
Importance
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion di...
Eoin P. Flanagan, Brenda L. Banwell, Laura Cacciaguerra et al.· JAMA Neurology· 0 citations
The safety profile of inebilizumab was consistent with prior evidence and no new safety concerns were identified, and inebilizumab reduced relapse rates and decreased concomitant use of oral glucocorticoids and immunosuppressants in patients with NMOSD.
K. Fujihara, Shinya Hirota, Muneyoshi Kudo et al.· Neurological Therapeutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.